165 related articles for article (PubMed ID: 29742654)
1. Effects of Cancer Genetic Panel Testing on at-Risk Individuals.
Frost AS; Toaff M; Biagi T; Stark E; McHenry A; Kaltman R
Obstet Gynecol; 2018 Jun; 131(6):1103-1110. PubMed ID: 29742654
[TBL] [Abstract][Full Text] [Related]
2. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
3. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
4. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
5. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
6. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
Hull LE; Haas JS; Simon SR
Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717
[TBL] [Abstract][Full Text] [Related]
7. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting.
DeFrancesco MS; Waldman RN; Pearlstone MM; Karanik D; Bernhisel R; Logan J; Alico L; Adkins RT
Obstet Gynecol; 2018 Nov; 132(5):1121-1129. PubMed ID: 30303907
[TBL] [Abstract][Full Text] [Related]
8. Male Breast Cancer Risk Assessment and Screening Recommendations in High-Risk Men Who Undergo Genetic Counseling and Multigene Panel Testing.
Gaddam S; Heller SL; Babb JS; Gao Y
Clin Breast Cancer; 2021 Feb; 21(1):e74-e79. PubMed ID: 32828665
[TBL] [Abstract][Full Text] [Related]
9. Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals.
Stuckey A; Febbraro T; Laprise J; Wilbur JS; Lopes V; Robison K
Am J Clin Oncol; 2016 Aug; 39(4):363-7. PubMed ID: 24710121
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
12. Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice.
Doherty J; Bonadies DC; Matloff ET
J Genet Couns; 2015 Aug; 24(4):683-7. PubMed ID: 25475920
[TBL] [Abstract][Full Text] [Related]
13. Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing.
Loescher LJ; Lim KH; Leitner O; Ray J; D'Souza J; Armstrong CM
Oncol Nurs Forum; 2009 Mar; 36(2):E57-67. PubMed ID: 19273395
[TBL] [Abstract][Full Text] [Related]
14. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
[TBL] [Abstract][Full Text] [Related]
15. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
16. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
17. Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction.
Dayan E; Chittenden A; Garber JE; Wo L; Caterson SA; Carty MJ; Erdmann-Sager J
Plast Reconstr Surg; 2019 Jul; 144(1):12-20. PubMed ID: 31246791
[TBL] [Abstract][Full Text] [Related]
18. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
19. Health Care Disparities and Demand for Expanding Hereditary Breast Cancer Screening Guidelines in African Americans.
Ciuro J; Beyer A; Fritzler J; Jackson N; Ahsan S
Clin Breast Cancer; 2021 Jun; 21(3):e220-e227. PubMed ID: 33168447
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
